Purchase this article with an account.
Andrea Russo, Anna Cancarini, Elena Gambicorti, Sarah Duse, Nicolò Scaroni, Ciro Costagliola, Francesco Semeraro; Comparison of visual and anatomical outcomes of half-dose photodynamic therapy and 689 nm laser treatment (pseudo-PDT) in eyes with chronic central serous chorioretinopathy.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5357. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Acute central serous chorioretinopathy (CSC) is a common disorder in middle-aged patients, characterized by serous retinal detachment in the macular region. We evaluated half-dose verteporfin photodynamic therapy (hd-PDT) versus 689 nm laser treatment in chronic CSC.
This was a pilot study of eyes with chronic CSC. A total of 20 patients were enrolled consecutively and randomized in a 1:1 ratio to receive hd-PDT (group 1) or 689 nm laser treatment delivering 95 J/cm2 by application of an intensity of 805 mW/cm2 over 118 seconds, using a spot size with a 3000 μm diameter (group 2). Best-corrected visual acuity (BCVA) and central macular thickness (CMT) findings were compared between groups.
The baseline characteristics were similar, and no significant differences between the groups were found. Both groups had significant BCVA improvements (7.3 ± 1.3 vs 7.6 ± 1.5 ETRDS letters in group 1 and 2, respectively; P = 0.64), as well as CMT reductions (-102.5 ± 13.6 vs -96.1 ± 20.5 µm in group 1 and 2, respectively; P = 0.42) at 16 weeks. Measured parameters were not significantly different between groups at any time point examined. Complete photoreceptor recovery, defined as a continuous ellipsoid zone with a discernible interdigitation zone, was observed at 16 weeks in 7 and 6 patients in group 1 and 2, respectively.
Both hd-PDT and 689 nm laser treatment were effective in treating chronic CSC. No significant differences in visual or anatomical outcomes were observed. Additional larger studies are warranted to corroborate our results.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
OCT series demonstrating the resolution of central serous chorioretinopathy in a 43-year-old male. A: baseline; B: 3 weeks after 689 nm laser treatment; C: 6 weeks after treatment.
OCT series depicting the reabsorption of a chronic foveal detachment in dome-shaped macula following 689 nm laser treatment, in a 51-year-old male. A: baseline; B: 4 weeks after 689 nm laser treatment.
This PDF is available to Subscribers Only